PCRX

Announcements

Nothing here yet

Daily updates

• Pacira BioSciences agreed to be acquired by Viatris in a transaction valued at $1.65 billion.Oct 9, 2026
• Pacira BioSciences announced its acquisition by Viatris in a deal valued at $1.65 billion.Oct 8, 2026

FDA designations

Nothing here yet

News

• Pacira signs an exclusive agreement with Molteni Farmaceutici to commercialize EXPAREL in the European Union and United KingdomOct 5, 2026
• Pacira BioSciences published positive two-year Phase 1 data for PCRX-201Aug 6, 2026
• Pacira BioSciences announces 12-month pilot study results showing favorable safety and significant pain improvements with iovera° compared to radiofrequency ablation in chronic low back painDec 2, 2025
• Pacira BioSciences concludes patient enrollment in Part A of Phase 2 study evaluating safety and efficacy of PCRX-201 for treatment of knee osteoarthritisNov 5, 2025
• Pacira BioSciences enters exclusive license agreement with AmacaThera for its novel long-acting analgesic for postsurgical pain controlNov 4, 2025